Anifrolumab PK study for Systemic Lupus Erythematosus (SLE)

Trial Identifier: D3468C00002
Sponsor: AstraZeneca
NCTID:: NCT05001698
Start Date: July 2021
Primary Completion Date: June 2022
Study Completion Date: June 2022
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Nantong, CN, 226001
CN Shanghai, CN, 200040
CN Shanghai, CN, 200025
CN Suzhou, CN, 215004